Please use this identifier to cite or link to this item:
|Title:||Eliminating hepatitis B by antagonizing cellular inhibitors of apoptosis.||Austin Authors:||Ebert, Gregor;Allison, Cody;Preston, Simon;Cooney, James;Toe, Jesse G;Stutz, Michael D;Ojaimi, Samar;Baschuk, Nikola;Nachbur, Ueli;Torresi, Joseph ;Silke, John;Begley, C Glenn;Pellegrini, Marc||Affiliation:||email@example.com.
Faculty of Science Technology and Engineering, School of Molecular Sciences, Department of Biochemistry, LaTrobe Institute for Molecular Science, Bundoora, VIC 3086, Australia
Department of Infectious Diseases and Department of Medicine, Austin Hospital, The University of Melbourne, Heidelberg, VIC 3084, Australia
Department of Medical Biology, The University of Melbourne, Parkville, VIC 3010, Australia
Division of Infection and Immunity and Cell Signaling and Cell Death, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia
Research and Development Division, TetraLogic Pharmaceuticals Corporation, Inc., Malvern, PA 19355.
|Issue Date:||20-Apr-2015||Publication information:||Proceedings of the National Academy of Sciences of the United States of America 2015; 112(18): 5803-8||Abstract:||We have shown that cellular inhibitor of apoptosis proteins (cIAPs) impair clearance of hepatitis B virus (HBV) infection by preventing TNF-mediated killing/death of infected cells. A key question, with profound therapeutic implications, is whether this finding can be translated to the development of drugs that promote elimination of infected cells. Drug inhibitors of cIAPs were developed as cancer therapeutics to promote TNF-mediated tumor killing. These drugs are also known as Smac mimetics, because they mimic the action of the endogenous protein Smac/Diablo that antagonizes cIAP function. Here, we show using an immunocompetent mouse model of chronic HBV infection that birinapant and other Smac mimetics are able to rapidly reduce serum HBV DNA and serum HBV surface antigen, and they promote the elimination of hepatocytes containing HBV core antigen. The efficacy of Smac mimetics in treating HBV infection is dependent on their chemistry, host CD4(+) T cells, and TNF. Birinapant enhances the ability of entecavir, an antiviral nucleoside analog, to reduce viral DNA production in HBV-infected animals. These results indicate that birinapant and other Smac mimetics may have efficacy in treating HBV infection and perhaps, other intracellular infections.||Gov't Doc #:||25902530||URI:||http://ahro.austin.org.au/austinjspui/handle/1/12757||DOI:||10.1073/pnas.1502400112||URL:||https://pubmed.ncbi.nlm.nih.gov/25902530||Type:||Journal Article||Subjects:||Smac mimetic
cellular inhibitor of apoptosis proteins
hepatitis B virus
|Appears in Collections:||Journal articles|
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.